-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Alnylam Pharmaceuticals HELIOS-B Phase 3 Study Of AMVUTTRA Shows Vutrisiran Improved Cardiac Structure And Function In ATTR-CM Patients With Amyloid Regression And Preserved Kidney Function

Benzinga·11/10/2025 08:58:47
Listen to the news
  • − Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile –
  • − Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –
  • – In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –
  • – Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –